Actively Recruiting
The Mito-Frail Trial: Effects of MitoQ on Vasodilation, Mobility and Cognitive Performance in Frail Older Adults
Led by UConn Health · Updated on 2026-01-09
60
Participants Needed
1
Research Sites
173 weeks
Total Duration
On this page
Sponsors
U
UConn Health
Lead Sponsor
N
National Institute on Aging (NIA)
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this clinical trial is to test the effects of MitoQ supplementation in older adults and frail older adults with physical dysfunction and/or cognitive dysfunction. The main question\[s\] it aims to answer are: * To compare vascular function, oxidative stress levels, and physical and cognitive function among older adults and frail older adults with physical and cognitive dysfunction * To determine whether MitoQ supplementation has the potential to improve vascular function in central and cerebral vessels * To determine whether MitoQ supplementation can enhance physical and cognitive capabilities.
CONDITIONS
Official Title
The Mito-Frail Trial: Effects of MitoQ on Vasodilation, Mobility and Cognitive Performance in Frail Older Adults
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Men and women aged 65 to 80 years
- Slow gait speed of 0.4 meters per second or less based on a 4-meter walk
- Mild cognitive impairment
- Good cardiovascular health without use of blood pressure, blood flow, or metabolism altering medications
You will not qualify if you...
- Vaccination in past two weeks
- Recent acute infection within three weeks before enrollment
- Known immunodeficiency including HIV, primary immunodeficiency, or history of chemotherapy or radiotherapy
- Use of medications in past 6 months that alter immune response such as high-dose corticosteroids
- Severe autoimmune disease requiring biological therapy
- Major severe illness or hospitalization in past 3 months
- Use of warfarin or other blood thinners
- Recent fall or conditions impairing ability to complete mobility tests
- Known bleeding disorders
- Conditions impairing ability to perform grip strength test
- Advanced neurological disease, severe co-morbid disease, terminal illness with reduced life expectancy, severe disability, or unintentional weight loss in last 12 months
- Participation in another study
- Diabetes requiring insulin
- Baseline ECG QTc greater than 450 ms in men or greater than 460 ms in women
- Prior diagnosis of ventricular arrhythmia such as ventricular tachycardia, ventricular fibrillation, or torsades de pointes
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
UConn Health
Farmington, Connecticut, United States, 06030
Actively Recruiting
Research Team
O
Oh Sung Kwon, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here